161 patents currently held
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
45
Ending by 2030
Nov 2026
Next term end
82
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2029 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Oct 2037 · Medium confidence
Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors
US 8,513,263
The most cited patent in this portfolio, cited by 129 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2029.
Kras G12C Inhibitors
US 10,689,377
Cited by 35 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Substituted Pyrazolo[1,5-a]pyridine Compounds as Ret Kinase Inhibitors
US 10,172,851
Cited by 26 later US patents, top 10% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Bicyclic Urea, Thiourea, Guanidine and Cyanoguanidine Compounds Useful for the Treatment of Pain (US 10,351,575) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 3 fees due Mar 3 to 15, 2027 · next Mar 3
- 3 fees due Apr 10 to 27, 2027 · next Apr 10
- 1 fee due May 26, 2027The maintenance fee for Pharmaceutical Combinations (US 10,485,788) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 3 fees due Jun 5 to 30, 2027 · next Jun 5
- 3 fees due Jul 5 to 30, 2027 · next Jul 5
- 4 fees due Aug 4 to 18, 2027 · next Aug 4
- 5 fees due Sep 3 to 19, 2027 · next Sep 3
- 6 fees due Oct 5 to 28, 2027 · next Oct 5
- 3 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 4 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 82 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds and Compositions as Protein Kinase Inhibitors | 8 in force | to Jul 2031 |
| Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors (2011) | 8 in force | to Dec 2029 |
| Preparation of and Formulation Comprising a Mek Inhibitor | 7 in force | to Apr 2034 |
| Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors (2012) | 6 in force | to Nov 2030 |
| Substituted IMIDAZO[1,2B]PYRIDAZINE Compounds as TRK Kinase Inhibitors | 6 in force | to Sep 2029 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,780,073 | N4-PHENYL-QUINAZOLINE-4-Amine Derivatives and Related Compounds as Erbb Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases In force · High confidence | In force | High confidence | |
| US 12,171,739 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases In force · High confidence | In force | High confidence | |
| US 7,425,631 | Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,039,639 | Kinase Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,693,989 | N4-PHENYL-QUINAZOLINE-4-Amine Derivatives and Related Compounds as Erbb Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases In force · High confidence | In force | High confidence | |
| US 8,044,083 | Kinase Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,026,233 | P38 Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 7,598,383 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,003,662 | Heterobicyclic Thiophene Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,329,709 | 5H-CYCLOPENTA[D]PYRIMIDINES as Akt Protein Kinase Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 161: 26 patents in force now held by others · 141 patents ended · 9 applications pending · 113 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.